ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

In this episode, OncLive On Air^® partnered with Two Onc Docs to bring you insights on the phase 3 NADINA trial (NCT04949113), findings from which were presented at the 2024 ASCO Annual Meeting by Christian U. Blank, MD, PhD, of The Netherlands Cancer Institute in Amsterdam. NADINA evaluated neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) vs adjuvant nivolumab in patients with macroscopic, resectable, stage III melanoma. In this episode, Drs Armstrong and Tawagi discussed the staging and prior standard of care for locally advanced melanoma; key findings from NADINA; and how these data may impact clinical practice.